JP2012527438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527438A5 JP2012527438A5 JP2012511329A JP2012511329A JP2012527438A5 JP 2012527438 A5 JP2012527438 A5 JP 2012527438A5 JP 2012511329 A JP2012511329 A JP 2012511329A JP 2012511329 A JP2012511329 A JP 2012511329A JP 2012527438 A5 JP2012527438 A5 JP 2012527438A5
- Authority
- JP
- Japan
- Prior art keywords
- perhexiline
- hfnef
- therapeutic agent
- left ventricular
- ejection fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 claims description 8
- 229960000989 perhexiline Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 230000002861 ventricular Effects 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 2
- LJCWONGJFPCTTL-ZETCQYMHSA-N L-4-hydroxyphenylglycine Chemical compound OC(=O)[C@@H](N)C1=CC=C(O)C=C1 LJCWONGJFPCTTL-ZETCQYMHSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229950010617 oxfenicine Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2009/050539 WO2010133815A1 (en) | 2009-05-20 | 2009-05-20 | Treatment of heart failure with normal ejection fraction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075231A Division JP2015147787A (ja) | 2015-04-01 | 2015-04-01 | 正常駆出率心不全の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012527438A JP2012527438A (ja) | 2012-11-08 |
| JP2012527438A5 true JP2012527438A5 (enExample) | 2014-07-24 |
Family
ID=41213178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511329A Pending JP2012527438A (ja) | 2009-05-20 | 2009-05-20 | 正常駆出率心不全の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8440697B2 (enExample) |
| EP (1) | EP2432470A1 (enExample) |
| JP (1) | JP2012527438A (enExample) |
| CN (1) | CN102573844A (enExample) |
| AU (1) | AU2009346606B2 (enExample) |
| BR (1) | BRPI0924398A2 (enExample) |
| CA (1) | CA2816448A1 (enExample) |
| IL (1) | IL216362A0 (enExample) |
| MX (1) | MX2011012310A (enExample) |
| WO (1) | WO2010133815A1 (enExample) |
| ZA (1) | ZA201109332B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
| GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| EP2432470A1 (en) | 2009-05-20 | 2012-03-28 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
| AU2012297569B2 (en) | 2011-08-16 | 2017-11-09 | Baker Heart and Diabetes Institute | Controlled-release formulation |
| EP2892529A4 (en) * | 2012-09-05 | 2016-01-20 | Adelaide Res &Innovation Pty Ltd | USES OF (-) - PERHEXILINE |
| MX2017008248A (es) * | 2014-12-22 | 2018-02-19 | Cardiora Pty Ltd | Metodo de tratamiento. |
| BR112019012214A8 (pt) | 2016-12-15 | 2023-03-28 | Baxter Int | Sistema e método para monitorar e determinar parâmetros do paciente a partir de forma de onda venosa detectada |
| US11039754B2 (en) | 2018-05-14 | 2021-06-22 | Baxter International Inc. | System and method for monitoring and determining patient parameters from sensed venous waveform |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN380695A0 (en) | 1995-06-23 | 1995-07-20 | Queen Elizabeth Hospital, The | Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions |
| US20030162824A1 (en) * | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
| CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
| GB0405381D0 (en) * | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
| AU2005230811A1 (en) | 2004-04-06 | 2005-10-20 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
| PL1959951T3 (pl) | 2005-12-01 | 2010-06-30 | Hoffmann La Roche | Heteroarylo-podstawione pochodne piperydyny jako inhibitory l-cpt1 |
| ITRM20060090A1 (it) | 2006-02-22 | 2007-08-23 | Sigma Tau Ind Farmaceuti | Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita |
| GB0723100D0 (en) * | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
| GB0908193D0 (en) * | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| EP2432470A1 (en) | 2009-05-20 | 2012-03-28 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
| US20140019207A1 (en) | 2012-07-11 | 2014-01-16 | Sap Ag | Interactive in-memory based sales forecasting |
| EP2892529A4 (en) | 2012-09-05 | 2016-01-20 | Adelaide Res &Innovation Pty Ltd | USES OF (-) - PERHEXILINE |
| WO2015131231A1 (en) | 2014-03-03 | 2015-09-11 | Adelaide Research & Innovation Pty Ltd | Methods for using (-)-perhexiline |
-
2009
- 2009-05-20 EP EP09785222A patent/EP2432470A1/en not_active Withdrawn
- 2009-05-20 BR BRPI0924398A patent/BRPI0924398A2/pt not_active IP Right Cessation
- 2009-05-20 JP JP2012511329A patent/JP2012527438A/ja active Pending
- 2009-05-20 MX MX2011012310A patent/MX2011012310A/es unknown
- 2009-05-20 AU AU2009346606A patent/AU2009346606B2/en not_active Ceased
- 2009-05-20 CN CN2009801606783A patent/CN102573844A/zh active Pending
- 2009-05-20 WO PCT/GB2009/050539 patent/WO2010133815A1/en not_active Ceased
- 2009-05-20 CA CA2816448A patent/CA2816448A1/en not_active Abandoned
-
2010
- 2010-05-21 US US12/785,077 patent/US8440697B2/en not_active Expired - Fee Related
-
2011
- 2011-11-14 IL IL216362A patent/IL216362A0/en unknown
- 2011-12-19 ZA ZA2011/09332A patent/ZA201109332B/en unknown
-
2013
- 2013-03-15 US US13/839,313 patent/US9468634B2/en not_active Expired - Fee Related
- 2013-03-15 US US13/838,458 patent/US9457017B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012527438A5 (enExample) | ||
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| IL259851A (en) | Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders | |
| WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
| JP2009537554A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| WO2009152189A8 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
| JP2010525084A5 (enExample) | ||
| JP2010535814A5 (enExample) | ||
| JP2012144574A5 (enExample) | ||
| JP2015057436A5 (enExample) | ||
| JP2013507408A5 (enExample) | ||
| JP2012502047A5 (enExample) | ||
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| JP2013508289A5 (enExample) | ||
| CL2008003201A1 (es) | Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno. | |
| JP2012502909A5 (enExample) | ||
| MX2013003060A (es) | Terapia de combinacion para tratar infeccion por hcv. | |
| JP2016530291A5 (enExample) | ||
| JP2013166781A5 (enExample) | ||
| EA201001100A1 (ru) | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение | |
| JP2011500589A5 (enExample) | ||
| WO2009133470A3 (en) | Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level | |
| JP2013032308A5 (enExample) |